Discover

AGEN
Agenus Inc.
3.41
2 x 2.40
2 x 3.91
bid
ask
+
0.35
11.44%
2 @ 06:47 AM
3.40 -0.01 (0.29%)
Ytd8.60%
1y-29.55%
3.06
day range
3.42
2.71
52 week range
7.34
Open3.06Prev Close3.06Low3.06High3.42Mkt Cap142.00M
Vol659.40KAvg Vol942.68KEPS2.05P/E1.66Forward P/E-0.28
Beta1.39Short Ratio4.16Inst. Own37.10%DividendN/ADiv YieldN/A
Ex Div DateN/AEarning08-1050-d Avg3.42200-d Avg3.671yr Est8.00

AGEN News

Agenus Announces Three-Year Survival Data from Phase 1b BOT+BAL Study in MSS Metastatic Colorectal Cancer to be Presented at ESMO GI 2026
gurufocus.com
Agenus Announces Three-Year Survival Data from Phase 1b BOT+BAL Study in MSS Metastatic Colorectal C

[url="]Agenus[/url] Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced tha

benzinga.com
Agenus To Present 3-Yr Survival Data From Phase 1b C-800-01 Study Of Botensilimab Plus Balstilimab I

Data reflect an additional year of follow-up from the 123-patient cohort in the Phase 1b studyAgenus

Agenus Announces Three-Year Survival Data from Phase 1b BOT+BAL Study in MSS Metastatic Colorectal Cancer to be Presented at ESMO GI 2026
businesswire.com
Agenus Announces Three-Year Survival Data from Phase 1b BOT+BAL Study in MSS Metastatic Colorectal C

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovatio

benzinga.com
Agenus Reports Durable Survival And Deep Responses With Botensilimab Plus Balstilimab In Heavily Pre

First presentation of BOT+BAL melanoma data in heavily pretreated patients whose disease had resiste

benzinga.com
Agenus' Noetik TARIO-2 AI Model Identifies Tumor Microenvironment Signature Predicting 64% Response

Noetik's TARIO-2 platform analyzed routine pretreatment H&E images from 113 BOT+BAL-treated

benzinga.com
Agenus Announces Publication Of Phase 1b Data Evaluating Botensilimab In Combination With Balstilima

Published prospective cohort showed durable responses and manageable safety in patients with HCC fol

Earnings Scheduled For May 11, 2026
benzinga.com
Earnings Scheduled For May 11, 2026

benzinga.com
Agenus Announces Phase II Data Showing Immune Reprogramming and Durable Survival with Botensilimab,

First study combining botensilimab (BOT) and balstilimab (BAL) with agenT-797 in gastroesophageal ca

benzinga.com
Agenus Announces First Patient Enrolled In Global Phase 3 BATTMAN Trial

A Landmark Registrational Study Aiming to Redefine Outcomes in MSS mCRC Which Represents Approximate

benzinga.com
Agenus To Present Chemo-Sparing BOT+BAL Immunotherapy Data In 1L MSS Colorectal Cancer At AACR 2026

A novel, chemo-sparing strategy (BBoPCO): introducing BOT+BAL in 1L MSS mCRC to extend survival and

Earnings Scheduled For March 16, 2026
benzinga.com
Earnings Scheduled For March 16, 2026

benzinga.com
Agenus Triggers First $20M Contingent Payment Under Prior Collaboration Deal With Zydus Lifesciences

Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that it has trig

benzinga.com
Agenus Data From Phase 1b C-800-01 Study Evaluating Botensilimab Shows Survival With BOT+BAL Associa

Agenus Inc. (NASDAQ:AGEN), a leader in immuno-oncology, today announced new translational and clinic

benzinga.com
Agenus To Highlight New Data At AACR-IO Exploring Systemic And Tumor Inflammation Biomarkers With BO

Agenus Inc. (NASDAQ:AGEN), a leader in immuno-oncology, today announced that new translational and c

Looking Into Agenus Inc's Recent Short Interest
benzinga.com
Looking Into Agenus Inc's Recent Short Interest

benzinga.com
Agenus Expands Global Medical Affairs Infrastructure And Early-Access Support Capabilities In Respon

Medical Affairs scale-up supports France's multi-tumor AAC access framework and expanding paid n

12 Health Care Stocks Moving In Thursday's Intraday Session
benzinga.com
12 Health Care Stocks Moving In Thursday's Intraday Session

benzinga.com
Agenus Q3 EPS $1.94 Misses $1.98 Estimate, Sales $30.200M Miss $55.713M Estimate

Agenus (NASDAQ:AGEN) reported quarterly earnings of $1.94 per share which missed the analyst consens

Earnings Scheduled For November 10, 2025
benzinga.com
Earnings Scheduled For November 10, 2025

benzinga.com
Insights Ahead: Agenus's Quarterly Earnings

benzinga.com
Agenus Releases New Data From Its botensilimab And balstilimab Combination Showing Durable Survival

Durable survival in heavily pretreated patients, including those who failed prior immunotherapy and

benzinga.com
HC Wainwright & Co. Reiterates Buy on Agenus, Maintains $23 Price Target

HC Wainwright & Co. analyst Emily Bodnar reiterates Agenus (NASDAQ:AGEN) with a Buy and maint

benzinga.com
Agenus Says Investigational Combination BOT/BAL Now Available To Eligible Patients With Refractory M

Agenus Inc. (NASDAQ:AGEN), a leader in immuno‑oncology, today announced its investigational combinat

benzinga.com
HC Wainwright & Co. Reiterates Buy on Agenus, Maintains $23 Price Target

HC Wainwright & Co. analyst Emily Bodnar reiterates Agenus (NASDAQ:AGEN) with a Buy and maint

benzinga.com
Agenus to Host Aug. 27 Virtual Briefing Highlighting Cancer Drug Pipeline and Phase 3 CRC Study

Agenus Inc. ("Agenus") (Nasdaq: AGEN), a leader in immuno-oncology, today announced that the

benzinga.com
Agenus Q2 EPS $(1.00) Misses $0.58 Estimate, Sales $25.700M Miss $49.710M Estimate

Agenus (NASDAQ:AGEN) reported quarterly losses of $(1.00) per share which missed the analyst consens

benzinga.com
Earnings Scheduled For August 11, 2025

benzinga.com
Examining the Future: Agenus's Earnings Outlook

benzinga.com
Agenus To Present Clinical Progress Across Botensilimab And Balstilimab Immunotherapy Programs At ES

Agenus Inc. (NASDAQ:AGEN), a leader in immuno-oncology, today announced that four abstracts highligh

benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session

benzinga.com
Agenus Confirms Agreement With FDA On Design Of Global BATTMAN Phase 3 Trial

Agenus also confirmed that it has reached agreement with the U.S. Food and Drug Administration (FDA)

benzinga.com
Agenus Says BOT/BAL Combination Achieves 2-Yr Survival Rate Of 42% Along With Now More Mature 21-Mon

Agenus Inc. (NASDAQ:AGEN) a leader in immuno-oncology innovation, today announced that its botensili

benzinga.com
Agenus Announces Research Collaboration To Develop Predictive Biomarkers Of Response To Clinical Sta

Partnership aims to accelerate precision immunotherapy by leveraging AI-powered virtual cell models

benzinga.com
Agenus Enters Into Asset Purchase Agreement With Zydus Pharmaceuticals, Sells Manufacturing Operatio

On June 3, 2025, Agenus Inc. (the "Company") and its wholly-owned subsidiary Agenus West, LL

Analyst Upgrades Agenus As Zydus Deal Alleviates Cash Overhang
benzinga.com
Analyst Upgrades Agenus As Zydus Deal Alleviates Cash Overhang

Zydus acquires two Agenus biologics facilities in California for $75 million, expanding U.S. CDMO pr

benzinga.com
Baird Maintains Neutral on Agenus, Raises Price Target to $6

Baird analyst Colleen Kusy maintains Agenus (NASDAQ:AGEN) with a Neutral and raises the price tar

benzinga.com
HC Wainwright & Co. Upgrades Agenus to Buy, Announces $25 Price Target

HC Wainwright & Co. analyst Emily Bodnar upgrades Agenus (NASDAQ:AGEN) from Neutral to Buy an

Agenus Stock Is Trading Higher Tuesday: What's Going On?
benzinga.com
Agenus Stock Is Trading Higher Tuesday: What's Going On?

Agenus announced it signed a partnership agreement with Zydus Lifesciences to expand patient access

benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session

benzinga.com
Agenus Inks Partnership Agreement With Zydus Lifesciences To Accelerate Clinical Development, Scale

Agenus will also grant Zydus an exclusive license to develop and commercialize BOT and BAL in India

Why Credo Technology Group Shares Are Trading Higher By Over 14%; Here Are 20 Stocks Moving Premarket
benzinga.com
Why Credo Technology Group Shares Are Trading Higher By Over 14%; Here Are 20 Stocks Moving Premarke

benzinga.com
Agenus Announces New Data From Ongoing Phase 1 Trial Evaluating BOT/BAL In Patients With MSS mCRC At

Presenting new data in the most mature readout to date, with 60% more patients and reported median a

benzinga.com
Baird Maintains Neutral on Agenus, Raises Price Target to $4

Baird analyst Colleen Kusy maintains Agenus (NASDAQ:AGEN) with a Neutral and raises the price tar

benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session

benzinga.com
Agenus Q1 EPS $(1.03) Beats $(1.38) Estimate, Sales $24.07M Miss $26.26M Estimate

Agenus (NASDAQ:AGEN) reported quarterly losses of $(1.03) per share which beat the analyst consensus

benzinga.com
Earnings Scheduled For May 12, 2025

benzinga.com
Agenus's Earnings: A Preview

benzinga.com
Agenus: Initial Results From NEOASIS Show BOT/BAL Efficacy In Neoadjuvant Setting Across Multiple MS

Agenus Inc. (NASDAQ:AGEN), a leader in immuno-oncology, today announced that data from the investiga

benzinga.com
Baird Maintains Neutral on Agenus, Lowers Price Target to $3

Baird analyst Colleen Kusy maintains Agenus (NASDAQ:AGEN) with a Neutral and lowers the price tar

benzinga.com
Agenus Initiated Further Operational Cost Reductions Expected To Lower Annual Burn To Approximately

Key Operational Highlights:Achieved Q4 2024 operational cash burn of $28.7 million, substantially re